

SYNTHESES OF PYRIDO[2,3-d]PYRIMIDINE NUCLEOSIDES VIA 6-ALLYLAMINO-
URIDINES FROM 6,5'-ANHYDROURIDINE DERIVATIVE AND ALLYLAMINES

Tsuneo Itoh*, Ichiro Ishikawa, Yasuo Tomii, Yoshihisa
Mizuno, and Haruo Ogura


School of Pharmaceutical Sciences, Kitasato University,
5-9-1, Shirokane, Minato-ku, Tokyo 108, Japan

Norio Kawahara


Hokkaido Institute of Pharmaceutical Sciences, 7-1,
Katsuraoka-cho, Otaru-shi, Hokkaido 047-02, Japan

Abstract — Pyrido[2,3-d]pyrimidine nucleosides were readily synthesized by treatment of 2',3'-O-isopropylidene-6-allylamino-uridines, which were derived from 6,5'-anhydro-2',3'-O-isopropylidene-6-hydroxyuridine and allylamines with palladium(II) acetate.


In recent years, we have interested in pyrido and pyrrolo[2,3-d]pyrimidine ring systems¹⁾ (1 and 2) which are viewed as being analogous to antibiotics (sangivamycin,²⁾ toyocamycin³⁾ and tubercidin⁴⁾), having potential antitumor activity. We have previously reported the synthesis of the isouridine type pyridopyrimidine nucleosides⁵⁾ (3). Some of these compounds showed a significant degree of induction toward differentiation of HL-60 cells.⁵⁾



1




2



3

We wish to report the simple synthesis of pyrido[2,3-d]pyrimidine nucleosides (2, R⁴=ribofuranoside) via 6,5'-anhydro-2',3'-O-isopropylidene-6-hydroxyuridine (4)⁶⁾ and allylamine with palladium(II) acetate.

Treatment of 6,5'-anhydro-2',3'-O-isopropylidene-6-hydroxyuridine (4) with allylamine at 60°C for 20 h afforded 6-allylamino-2',3'-O-isopropylideneuridine (5a, mp 214-216°C)⁷⁾ in 37.4% yield. Similarly, treatment of 4 with α -methylallylamine under the same conditions for 72 h led to the formation of 2',3'-O-isopropylidene-6-(α -methylallylamino)uridine (5b, mp 199-200°C)⁷⁾ as a mixture of two stereoisomers in 32.1% yield. Furthermore, 2',3'-O-isopropylidene-6-(β -methylallylamino)uridine (5c, mp 218-219°C)⁷⁾ was obtained from the reaction of 4 with β -methylallylamine in 45.6% yield. 6-Crotylamino-2',3'-O-isopropylideneuridine (5d, mp 198-199°C)⁷⁾ was also obtained from the reaction of 4 with crotylamine in 35.6% yield.



A mixture of 5a and palladium(II) acetate in acetic acid was refluxed for 2 h. After neutralization with saturated NaHCO₃ solution, the reaction mixture was extracted with AcOEt and the solution was concentrated in vacuo. The residue was subjected to silica gel column chromatography with CHCl₃ to afford crystalline compounds,

6a (mp 148-150°C)⁸⁾ in 20.0% yield and 7a (mp 157-159°C)⁹⁾ in 7.6% yield.

Compound 6a has the empirical formula, C₁₅H₁₇N₅O₆, which was derived from elemental and mass spectral analyses. ¹H-Nmr spectrum of 6a has a signal at δ 7.29 (dd, $J=4.8$

and 7.2Hz, 1H), 8.48 (dd, $J=2.1$ and 7.2Hz, 1H) and 8.67 (dd, $J=2.1$ and 4.8Hz, 1H) which can be attributable to the aromatic protons on a pyridine ring, and a signal at δ 5.01 (br, 1H) which can be assigned to 5'-OH proton.

From these data, the compound (6a) was assigned to be 1-(2',3'-O-isopropylidene- β -D-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione. An empirical formula, $C_{17}H_{19}N_3O_7$, of compound 7a was also derived from analyses data. 1H -Nmr spectrum of 7a has a signal at δ 7.30 (dd, $J=4.8$ and 7.2Hz, 1H), 8.49 (dd, $J=2.1$ and 7.2Hz, 1H) and 8.68 (dd, $J=2.1$ and 7.2Hz, 1H) which can be attributable to the aromatic protons on a pyridine ring and a signal at δ 2.04 (s, 3H) which can be assigned to acetyl protons. From these data, the compound (7a) was assigned to be 1-(5'-O-acetyl-2',3'-O-isopropylidene- β -D-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione. When 5b was treated in a similar manner for 6 h, 7-methyl-1-(5'-O-acetyl-2',3'-O-isopropylidene- β -D-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (7b, mp 179-180°C)⁹⁾ alone was obtained in 32.8% yield.

Furthermore, 5c was treated by palladium(II) acetate in the same manner for 30 min to give 6-methyl-1-(2',3'-O-isopropylidene- β -D-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (6c, mp 194-195°C)⁹⁾ in 35.6% yield. Compound 5d was also treated by palladium(II) acetate for 3 h. The residue was subjected to silica gel column chromatography with $CHCl_3$, to give 5-methyl-1-(2',3'-O-isopropylidene- β -D-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (6d, mp 177-178°C)⁹⁾ in 26.9% yield and 5-methyl-1-(5'-O-acetyl-2',3'-O-isopropylidene- β -D-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,4(1H,3H)-dione (7d, mp 181-182°C)⁹⁾ in 10.1% yield, respectively.

ACKNOWLEDGEMENT

We are grateful to Mrs. A. Nakatani, Miss A. Nakagawa, Mrs. C. Sakabe, and Mrs. N. Satoh, School of Pharmaceutical Science, Kitasato University, for microanalyses and spectral measurements. This work was supported in part by a Grant-in-Aid for Cancer Research (No. 61010096, No. 62010033, and No. 63010031) from the Ministry of Education, Science and Culture, Japan.

REFERENCES AND NOTES

- 1) a) B. H. Rizkalla and A. D. Broom, *J. Org. Chem.*, 1972, 37, 3980; b) G. L. Anderson and A. D. Broom, *ibid.*, 1977, 42, 997; c) T.-L. Su, K. Harada, and K.

- A. Watanabe, Nucleosides & Nucleotides, 1984, 3, 513.
- 2) a) J. A. Cavins, Proc. Am. Ass. Cancer Res., 1966, 7, 12; b) K. V. Rao and D. W. Renn, Antimicrob. Agents Chemother., 1963, 77.
- 3) a) H. Nishimura, K. Katagiri, K. Sato, N. Mayama, and N. Shimaoka, J. Antibiot., 1956, 9, 60; b) R. L. Tolman, R. K. Robins, and L. B. Townsend, J. Am. Chem. Soc., 1968, 90, 524.
- 4) a) K. Anzai, G. Nakamura, and S. Suzuki, J. Antibiot., 1957, 10, 201; b) S. Suzuki and S. Marumo, ibid., 1960, 13, 360.
- 5) T. Itoh, R. G. Melik-Ohanjanian, I. Ishikawa, N. Kawahara, Y. Mizuno, and H. Ogura, Chem. Pharm. Bull., (Tokyo) submitted.
- 6) B. A. Otter, E. A. Falco, and J. J. Fox, J. Org. Chem., 1969, 34, 1390.
- 7) 5a: ¹H-Nmr (DMSO-d₆) δ 1.29, 1.50(3H each, s, C-CH₃), 3.55-3.77(4H, br, H-5', -NHCH₂-), 4.04(1H, dt, J=3.3 and 3.9Hz, H-4'), 4.53(1H, s, H-5), 4.79(1H, dd, J=3.9 and 6.6Hz, H-3'), 5.03(1H, dd, J=3.6 and 6.6Hz, H-2'), 5.17-5.33(2H, m, CH=CH₂), 5.47(1H, t, J=4.5Hz, OH-5'), 5.66-6.02(1H, m, CH=CH₂), 6.28(1H, d, J=3.6Hz, H-1'), 7.18(1H, t, J=5.4Hz, NHCH₂-), 10.67(1H, s, CONH).
- 5b: ¹H-Nmr (DMSO-d₆) δ 1.28, 1.50(3H each, s, C-CH₃), 1.65(3H, d, J=6.5Hz, NHCHCH₃), 3.56-3.71(3H, br, NHCH-, H-5'), 4.04(1H, dt, J=3.3 and 3.9Hz, H-4'), 4.56(1H, s, H-5), 4.80(1H, dd, J=3.9 and 6.6Hz, H-3'), 5.03(1H, dd, J=3.6 and 6.6Hz, H-2'), 5.34-5.54(3H, m, CH=CH₂, OH-5'), 5.55-5.70(1H, m, CH=CH₂), 6.25(1H, d, J=3.6Hz, H-1'), 7.15(1H, br, NHCH-), 10.70(1H, s, CONH).
- 5c: ¹H-Nmr (DMSO-d₆) δ 1.29, 1.50(3H each, s, C-CH₃), 1.67(3H, s, C-CH₃), 3.59(2H, d, J=5.4Hz, NHCH₂-), 3.60-3.66(2H, br, H-5'), 4.08(1H, dt, J=3.3 and 3.9 Hz, H-4'), 4.48(1H, s, H-5), 4.82(1H, dd, J=3.9 and 6.6Hz, H-3'), 4.84, 4.87(1H each, s, C=CH₂), 5.06(1H, dd, J=3.3 and 6.6Hz, H-2'), 5.55(1H, t, J=4.5Hz, OH-5'), 6.30(1H, d, J=3.3Hz, H-1'), 7.32(1H, t, J=5.4Hz, NHCH₂-), 10.69(1H, s, CONH).
- 5d: ¹H-Nmr (DMSO-d₆) δ 1.28, 1.49(3H each, s, C-CH₃), 1.65(3H, d, J=6.0Hz, CH=CHCH₃), 3.55-3.71(4H, br, NHCH₂-, H-5'), 4.05(1H, dt, J=3.3 and 3.9Hz, H-4'), 4.56(1H, s, H-5), 4.80(1H, dd, J=3.9 and 6.6Hz, H-3'), 5.02(1H, dd, J=3.6 and 6.6Hz, H-2'), 5.37-5.70(2H, m, CH=CH-), 5.51(1H, t, J=4.5Hz, OH-5'), 6.24(1H, d, J=3.6Hz, H-1'), 7.16(1H, t, J=5.4Hz, NHCH-), 10.70(1H, s, CONH).
- 8) 6a: ¹H-Nmr (CDCl₃) δ 1.35, 1.61(3H each, s, C-CH₃), 3.87(2H, br, H-5'), 4.28(1H, dt, J=3.2 and 3.9Hz, H-4'), 5.01(1H, br, OH-5'), 5.12(1H, dd, J=3.9 and 6.6

Hz, H-3'), 5.35(1H, dd, $J=2.7$ and 6.6 Hz, H-2'), 7.14(1H, d, $J=2.7$ Hz, H-1'), 7.29(1H, dd, $J=4.8$ and 7.2 Hz, H-6), 8.48(1H, dd, $J=2.1$ and 7.2 Hz, H-5), 8.67(1H, dd, $J=2.1$ and 4.8 Hz, H-7), 8.70(1H, br s, CONH).

6c: $^1\text{H-Nmr}$ (CDCl_3) δ 1.37, 1.62(3H each, s, C-CH_3), 2.42(3H, s, C-CH_3), 3.20(1H, br, OH-5'), 3.81(1H, ddd, $J=3.3$, 8.4, and 12.0 Hz, H-5'), 3.92(1H, dt, $J=3.0$ and 12.0 Hz, H-5'), 4.31(1H, dt, $J=3.3$ and 3.9 Hz, H-4'), 5.14(1H, dd, $J=3.9$ and 6.6 Hz, H-3'), 5.35(1H, dd, $J=3.3$ and 6.6 Hz, H-2'), 7.08(1H, br d, $J=3.3$ Hz, H-1'), 8.28(1H, d, $J=2.1$ Hz, H-5), 8.49(1H, d, $J=2.1$ Hz, H-7), 8.50(1H, br, CONH).

6d: $^1\text{H-Nmr}$ (CDCl_3) δ 1.37, 1.61(3H each, s, C-CH_3), 2.81(3H, s, C-CH_3), 3.24(1H, br, OH-5'), 3.82(1H, ddd, $J=3.6$, 8.4, and 12.0 Hz, H-5'), 3.92(1H, dt, $J=3.2$ and 12.0 Hz, H-5'), 4.28(1H, dt, $J=3.2$ and 3.9 Hz, H-4'), 5.15(1H, dd, $J=3.9$ and 6.6 Hz, H-3'), 5.34(1H, dd, $J=3.0$ and 6.6 Hz, H-2'), 7.05(1H, d, $J=5.1$ Hz, H-6), 7.16(1H, br d, $J=3.0$ Hz, H-1'), 8.43(1H, d, $J=5.1$ Hz, H-7), 9.00(1H, br, CONH).

9) 7a: $^1\text{H-Nmr}$ (CDCl_3) δ 1.37, 1.57(3H each, s, C-CH_3), 2.04(3H, s, COCH_3), 4.23(1H, dd, $J=7.5$ and 11.0 Hz, H-5'), 4.32(1H, dt, $J=4.2$ and 7.5 Hz, H-4'), 4.41(1H, dd, $J=4.2$ and 11.0 Hz, H-5'), 5.01(1H, dd, $J=4.2$ and 6.6 Hz, H-3'), 5.31(1H, dd, $J=1.2$ and 6.6 Hz, H-2'), 7.20(1H, d, $J=1.2$ Hz, H-1'), 7.30(1H, dd, $J=4.8$ and 7.2 Hz, H-6), 8.49(1H, dd, $J=2.1$ and 7.2 Hz, H-5), 8.68(1H, dd, $J=2.1$ and 4.8 Hz, H-7), 8.73(1H, br s, CONH).

7b: $^1\text{H-Nmr}$ (CDCl_3) δ 1.37, 1.61(3H each, s, C-CH_3), 2.05(3H, s, COCH_3), 2.80(3H, s, C-CH_3), 4.22(1H, dd, $J=7.2$ and 11.0 Hz, H-5'), 4.33(1H, dt, $J=4.2$ and 7.2 Hz, H-4'), 4.42(1H, dd, $J=4.2$ and 11.0 Hz, H-5'), 5.01(1H, dd, $J=4.2$ and 6.6 Hz, H-3'), 5.28(1H, dd, $J=1.2$ and 6.6 Hz, H-2'), 7.03(1H, d, $J=5.1$ Hz, H-6), 7.23(1H, br d, $J=1.2$ Hz, H-1'), 8.43(1H, d, $J=5.1$ Hz, H-5), 8.44(1H, br, CONH).

7d: $^1\text{H-Nmr}$ (CDCl_3) δ 1.37, 1.60(3H each, s, C-CH_3), 2.05(3H, s, COCH_3), 2.81(3H, s, C-CH_3), 4.22(1H, dd, $J=7.5$ and 11.0 Hz, H-5'), 4.33(1H, dt, $J=4.5$ and 7.5 Hz, H-4'), 4.42(1H, dd, $J=4.5$ and 11.0 Hz, H-5'), 5.01(1H, dd, $J=4.5$ and 6.6 Hz, H-3'), 5.28(1H, dd, $J=1.2$ and 6.6 Hz, H-2'), 7.04(1H, d, $J=6.0$ Hz, H-6), 7.22(1H, br d, $J=1.2$ Hz, H-1'), 8.43(1H, d, $J=6.0$ Hz, H-5), 8.49(1H, br, CONH).

Received, 30th June, 1989